Abstract
A cross-sectional study was carried out in Kirkuk city from 15th
of June 2018 to 15th
of
December 2018 to detect of Toxoplasma gondii DNA in sera of women with breast cancer
by real-time PCR and comparing the results with IgG and IgM toward T. gondii. The number
of breast cancer women understudy were 35. The ages of the patients were between 20-75
years old. These patients admitted to Kirkuk oncology center. The control group were
included 50 healthy individuals. blood was collected from each patients and control for
molecular tests of T. gondii using real-time PCR and serological testing for detection specific
Toxoplasma gondii IgM and IgG by using ELISA technique. The study showed that the
highest rate of anti T. gondii IgM+ IgG- antibodies 8.57% was recorded among women with
breast cancer comparing with 8% in healthy control while 14.29% of women with breast
cancer were IgM+IgG+ comparing 6% of the healthy control group. The highest rate of total
T. gondii antibodies by ELISA 68.57% was noted among women with breast cancer and the
lowest rate was among healthy control 20%. The study revealed that 54.17% of women with
breast cancer with positive ELISA was positive by PCR comparing with 9.09% of patients
with negative ELISA results. The result was highly significant with sensitivity and specificity
of 54.17% and 90.09% respectively. The highest rate of anti T. gondii IgM+ IgG- antibodies
66.67% women with breast cancer was positive by PCR followed by 40% of patients with
IgM+ IgG+ antibodies. It was concluded that Toxoplasma gondii more frequently associated
with breast cancer and PCR was more accurate in detection of the parasite.
of June 2018 to 15th
of
December 2018 to detect of Toxoplasma gondii DNA in sera of women with breast cancer
by real-time PCR and comparing the results with IgG and IgM toward T. gondii. The number
of breast cancer women understudy were 35. The ages of the patients were between 20-75
years old. These patients admitted to Kirkuk oncology center. The control group were
included 50 healthy individuals. blood was collected from each patients and control for
molecular tests of T. gondii using real-time PCR and serological testing for detection specific
Toxoplasma gondii IgM and IgG by using ELISA technique. The study showed that the
highest rate of anti T. gondii IgM+ IgG- antibodies 8.57% was recorded among women with
breast cancer comparing with 8% in healthy control while 14.29% of women with breast
cancer were IgM+IgG+ comparing 6% of the healthy control group. The highest rate of total
T. gondii antibodies by ELISA 68.57% was noted among women with breast cancer and the
lowest rate was among healthy control 20%. The study revealed that 54.17% of women with
breast cancer with positive ELISA was positive by PCR comparing with 9.09% of patients
with negative ELISA results. The result was highly significant with sensitivity and specificity
of 54.17% and 90.09% respectively. The highest rate of anti T. gondii IgM+ IgG- antibodies
66.67% women with breast cancer was positive by PCR followed by 40% of patients with
IgM+ IgG+ antibodies. It was concluded that Toxoplasma gondii more frequently associated
with breast cancer and PCR was more accurate in detection of the parasite.
Keywords
Toxoplasma gondii; breast cancer; ELISA and real-time PCR
Abstract
أجريت الدراسة في مدينة كركوك للفترة من 15 حزيران 2018 الى 15 كانون الأول 2018 للكشف الجزيئي عن المقوسات الكوندية في النساء المصابات بسرطان الثدي ومقارنته مع نتيجة البحث عن الاجسام المضادة تجاه الطفيلي. شملت الدراسة 35 امرأة مصابة بسرطان الثدي واللاتي كانت اعمارهن 20-75 سنة وكن يراجعن مركز كركوك للأورام السرطانية، كما وشملت الدراسة 50 فرداً سليماً كمجموعة سيطرة. أجريت فحوصات تفاعلات البلمرة المتسلسلةreal- time PRC وفحص الاليزا ELISA للكشف عن الاجسام المضادة في جميع المرضى والاصحاء في الدراسة. أظهرت الدراسة أن نسبة الاجسام المضادة IgM+ IgG- كان 8،57% في النساء المصابات بسرطان الثدي مقارنة ب8% بمجموعة السيطرة كما وأن 14،29% من المرضى كن حاملات للأجسام المضادة نوع IgM+IgG+ تجاه الطفيلي مقارنة ب 6% في مجموعة السيطرة. كما سجلت الدراسة أن اعلى نسبة من مجموع الاجسام المضادة 67،57% سجلت في النساء المريضات مقارنة ب 20% في مجموعة السيطرة. أظهرت الدراسة أن 54،17% من النساء المصابات بسرطان الثدي واللاتي كن يحملن الاجسام المضادة تجاه الطفيلي كن فعليا ذوات نتيجة إيجابية بفحص PCR في الكشف عن الحمض النووي للطفيلي وبنسبة حساسية ودقة 54،17% و 90،09% على التوالي وأن اعلى نسبة من الاجسام المضادة كانت نوع IgM+ IgG- 66،67% تجاه الطفيلي مقارنة ب 40% من نوع IgM+ IgG+.الاستنتاج: يستنتج من الدراسة ان المقوسات الكوندية لها علاقة وارتباط مع سرطان الثدي ان فحص PCR هو الطريقة الأدق للكشف عن الطفيلي في المرضى
Keywords
المقوسات الكوندية، سرطان الثدي، فحص الاليزا و تفاعلات البلمرة المتسلسلة.